查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190804

细胞外基质 (ECM) 贴片市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Extracellular Matrix Patches Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计在预测期内（2022 年至 2027 年），细胞外基质 (ECM) 贴片市场的复合年增长率为 6.65%。

COVID-19 对医疗保健行业产生了前所未有的影响。 此外，世界各国政府施加的限制影响了手术的数量。 将外科手术能力限制在急救和/或急诊手术中的认知需求导致择期心臟和血管手术和外科手术的延误。 该指南由每个国家的外科学会和专业学会制定。 根据 2020 年 5 月发表的一项研究，由于 COVID-19 大流行导致择期手术取消：为手术恢復计划提供信息的全球预测模型，由于 COVID-19 导致医院服务中断的高峰期为 12 週，约有 2840 万次择期手术2020 年在全球范围内取消或推迟。 在印度，由于 COVID-19 大流行，超过 580,000 例预定的手术已被取消或推迟。 由于细胞外基质 (ECM) 贴片通常用于重建、软组织和血管手术，这些手术的停止影响了市场增长。 因此，COVID-19 对市场增长产生了显着影响。

手术数量增加、在疝气和骨盆重建手术中采用细胞外基质 (ECM) 补片、产品发布以及市场参与者的战略举措等关键因素正在推动市场增长。

由于细胞外基质 (ECM) 贴片是促进癒合的手术网状物，因此手术次数的增加是增长的关键驱动力之一。 因此，预计全球范围内进行的大量手术将推动市场增长。 例如，根据 2020 年 9 月题为“通过列举全民健康覆盖下城市社区的外科手术来估计印度国家外科手术需求”的出版物，低收入和中等收入国家 (LMIC) 的 100,000 人估计有 5,000 人需要手术来满足疾病的手术负担。 此外，根据同一来源，报告的手术率从低收入和中等收入国家 (LMIC) 的每 100,000 人 295 人到高收入国家 (HIC) 的每 100,000 人 23,000 人不等。 同样，根据美国疾病控制和预防中心的 2022 年更新，共有 1820 万成年人患有冠状动脉疾病，其中约 70% 接受了手术。 如此高的手术负担产生了对 ECM 贴片的需求，并促进了市场的增长，因为它们也使用 ECM 贴片来支持癒合过程。

此外，公司正专注于开髮用于软组织修復的细胞外基质。 例如，2020年2月，Aroa Biosurgery在美国市场推出了软组织修復重建新产品Myriad。 Myriad 可用于各种需要软组织修復或加固的整形和重建手术，包括整形手术、肢体补救、烧伤和外伤。

此外，市场进入者的战略举措也有望促进市场的增长。 例如，2021 年 7 月，Becton, Dickinson, and Company 收购了 Tepha, Inc.。 Tepha 是专有可吸收聚合物技术的领先开发商和製造商之一。 此类收购也有助于市场的增长。

因此，由于上述因素，市场有望在预测期内实现增长。 然而，细胞外基质 (ECM) 贴片植入物的高成本可能会阻碍市场增长。

细胞外基质 (ECM) 贴片市场趋势

预计在预测期内心臟修復领域将占据很大的市场份额

在预测期内，心臟修復领域预计将占据很大的市场份额。 这是由于心血管疾病的数量、新产品发布和研究等因素推动了该细分市场的增长。 例如，根据英国心臟基金会 2022 年 8 月公布的“英国概况”，2021 年英国有超过 760 万人患有某种形式的心臟或循环系统疾病。 另据报导，760万人中，男性400万，女性360万。 全球心血管疾病负担如此之重，预计将产生对用于心臟修復的 ECM 的需求，从而推动该细分市场的增长。

此外，市场参与者越来越关注心臟修復产品开发的研究，预计也将推动这一细分市场的增长。 例如，2021 年 9 月，泰尔茂公司启动了名为 PANTHER 的全球外科移植物研究，这是一项针对各种针织和机织外科移植物和心血管补片的前瞻性和回顾性研究。 这些研究的积极结果预计将在未来导致更有效产品的开发，并有望推动细分市场的增长。

此外，监管部门的批准也有望推动该细分市场的增长。 例如，2021 年 6 月，Axio Biosolutions 的 Axiostat Patch 获得了美国食品和药物管理局的批准，该产品可帮助控制血管手术中的中度至重度出血。 此类发布也推动了细分市场的增长。

因此，由于上述因素，市场预计在预测期内会出现市场增长。

预计在预测期内北美将占据很大的市场份额

在预测期内，预计北美将占市场增长的很大一部分。 市场增长的驱动因素包括心血管疾病和缺陷的发病率增加、运动损伤、外伤病例、研发支出增加以及疝病发病率增加。

根据《社区生活服务管理局 2020 年报告》，到 2020 年，16.9% 的美国人口将达到 65 岁及以上，预计到 2060 年将翻一番，达到 9470 万。该年龄段将从美国的 16% 上升到占总人口的21.6%。 老年人口易患心血管疾病，细胞外基质（ECM）在心臟再生和损伤后修復中起着重要作用，有望推动市场增长。

市场进入者推出的产品预计也将促进市场增长。 例如，2021 年 11 月，Sanara MedTech Inc. 将在美国推出两款创新的细胞外基质：组织修復移植物 FORTIFY TRG 和 Cook Biotech Inc. 的 FORTIFY FLOWABLE 细胞外基质。 此类产品的推出将推动市场增长。

因此，由于上述因素，预计在预测期内北美地区的市场将出现显着增长。

细胞外基质 (ECM) 贴片市场竞争分析

由于主要参与者的存在，细胞外基质 (ECM) 贴片市场竞争适中。 主要参与者正在使用各种策略，例如新产品发布、扩张、协议、合资企业、联盟和收购，以增加他们在该市场的足迹。 主要参与者包括 Baxter International、Coloplast、MTF Biologics、Terumo Corporation 和 Aziyo Biologics。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 手术次数增加
    • 细胞外基质 (ECM) 补片在疝气和骨盆重建手术中的应用
  • 市场製约因素
    • 细胞外基质 (ECM) 贴片治疗的高成本
  • 五力分析分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按原材料
    • 猪
    • 奶牛
    • 其他
  • 通过使用
    • 软组织修復
    • 心臟修復
    • 血管修復和重建
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Baxter International
    • Becton, Dickinson, and Company
    • Terumo Corporation
    • LeMaitre
    • Smith+Nephew
    • Aziyo Biologics
    • Integra LifeSciences Corporation
    • Coloplast
    • Medtronic
    • MTF Biologics
    • Koninklijke DSM N.V.

第7章 市场机会今后动向

简介目录
Product Code: 90481

The extracellular matrix patches market is projected to witness a CAGR of 6.65% over the forecast period (2022 - 2027).

COVID-19 had an unprecedented impact on the healthcare industry. Additionally, the restrictions imposed by governments across the world affected the number of surgeries performed. The recognition of the need to limit operative capacity to only emergent and/or urgent procedures resulted in delayed elective cardiac and vascular procedures and surgeries. The guidelines were set forth by national surgical and specialty societies. According to the study published in May 2020, "Elective surgery cancellations due to the COVID-19 pandemic: global predictive modeling to inform surgical recovery plans" based on 12 weeks of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. More than 580,000 planned surgeries in India were canceled or delayed as a result of the COVID-19 pandemic. Such cancellation of surgeries affected the growth of the market as extracellular matrix patches are largely employed in reconstruction, soft tissue, and vascular surgeries. Thus, COVID-19 had a pronounced impact on the growth of the market.

The major factors such as the increasing number of surgeries, adoption of extracellular matrix patches in hernia and pelvic reconstruction surgeries, product launches, and strategic initiatives by market players are driving the growth of the market.

The increasing number of surgeries is one of the major factors propelling the growth, as an extracellular matrix patch is a surgical mesh that fosters healing. Thus, a higher number of surgeries being performed worldwide is expected to propel the growth of the market. For instance, as per a September 2020 published article titled "Estimation of the National Surgical Needs in India by Enumerating the Surgical Procedures in an Urban Community Under Universal Health Coverage," an estimated 5,000 surgeries are required to meet the surgical burden of diseases of 100,000 people in low- and middle-income countries (LMICs). Additionally, as per the same source, the reported rates of surgery vary from 295 in low-and middle-income countries (LMICs) to 23,000 in high-income countries (HIC) per 100,000 population. Likewise, according to the Center for Disease Control and Prevention's 2022 update, a total of 18.2 million adults had coronary artery disease, and approximately 70% of these patients underwent surgery. Such a high burden of surgeries creates a need for ECM patches as such surgeries also employ them to support the healing process, thus boosting the growth of the market.

Additionally, the companies are focusing on developing an extracellular matrix for soft tissue repair. For instance, in February 2020, Aroa Biosurgery launched Myriad, a new product for soft tissue repair and reconstruction, in United States market. Myriad can be used for a variety of plastic and reconstructive surgical operations that require the repair or reinforcement of soft tissue, including plastic surgery, limb salvage, burns, and trauma.

Furthermore, the strategic initiatives taken by the market players are also expected to boost the growth of the market. For instance, in July 2021, Becton, Dickinson, and Company acquired Tepha, Inc. Tepha is one of the leading developers and manufacturers of proprietary resorbable polymer technology. Such acquisitions also contribute to the growth of the market.

Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, the high cost of extracellular matrix patch grafts may impede the growth of the market.

Extracellular Matrix Patches Market Trends

The Cardiac Repair Segment is Expected to Have the Significant Market Share Over the Forecast Period

The cardiac repair segment is expected to hold a significant share in the market over the forecast period, owing to factors such as the number of cardiovascular diseases, the launch of new products, and research studies that are driving the growth of the market segment. For instance, according to the British Heart Foundation, United Kingdom Factsheet, released in August 2022, more than 7.6 million people were living in United Kingdom in 2021 with some kind of heart and circulatory disease. It also reported that of the 7.6 million, 4 million are males and 3.6 million are females. Such a high burden of cardiovascular diseases in different countries around the world creates the need for ECM for cardiac repair and is thus expected to drive the growth of the market segment.

Additionally, the increasing focus of market players on research studies for the development of cardiac repair products is also expected to boost the growth of the segment. For instance, in September 2021, Terumo Corporation launched a global surgical graft study known as PANTHER, which is a prospective and retrospective study of a comprehensive range of knitted and woven surgical grafts and cardiovascular patches. The positive results from such studies are expected to lead to the development of more effective products in the future, which is expected to drive the growth of the market segment.

Furthermore, approval from the regulatory authority is also expected to boost the growth of the market segment. For instance, in June 2021, Axio Biosolutions received United States Food and Drug Administration's clearance of its product Axiostat Patch, which helps in the control of moderate to severe bleeding in vascular procedures. Such launches also propel the growth of the market segment.

Thus, owing to the abovementioned factors, the market segment is expected to project growth of the market over the forecast period.

North America is Expected to Have the Significant Market Share Over the Forecast Period

North America is expected to witness a significant share of the market growth over the forecast period. The factors propelling the growth of the market are the increasing incidence of cardiovascular diseases and defects; sports injuries; trauma cases; growing research and development expenditure, and increasing incidences of hernia disorders.

According to the Administration for Community Living report 2020, the number of Americans aged 65 and above was 16.9% of the total population in 2020, and it is estimated to about double to 94.7 million by 2060, and the 65-and-older age group's share of the total population will rise from 16% to 21.6% in United States. As the geriatric population is more prone to cardiovascular disease, it is expected to boost the growth of the market as extracellular matrix (ECM) plays an important role in cardiac regeneration and repair after cardiac injury.

The launch of products by the market players is also expected to drive the growth of the market. For instance, in November 2021, Sanara MedTech Inc. launched two innovative extracellular matrix products, FORTIFY TRG, a tissue repair graft, and FORTIFY FLOWABLE Extracellular Matrix, from Cook Biotech Inc. in United States. Such product launches propel the growth of the market.

Thus, owing to the aforementioned factors, the market is expected to show significant growth in the North American region over the forecast period.

Extracellular Matrix Patches Market Competitive Analysis

The extracellular matrix patches market is moderately competitive with the presence of major players. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions to increase their footprints in this market. Some of the key players are Baxter International, Coloplast, MTF Biologics, Terumo Corporation, and Aziyo Biologics, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Surgeries
    • 4.2.2 Adoption of Extracellular Matrix Patch in Hernia and Pelvic Reconstruction Surgeries
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Extracellular Matrix Patch Procedure
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Raw Material
    • 5.1.1 Porcine
    • 5.1.2 Bovine
    • 5.1.3 Others
  • 5.2 By Application
    • 5.2.1 Soft Tissue Repair
    • 5.2.2 Cardiac Repair
    • 5.2.3 Vascular Repair & Reconstruction
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter International
    • 6.1.2 Becton, Dickinson, and Company
    • 6.1.3 Terumo Corporation
    • 6.1.4 LeMaitre
    • 6.1.5 Smith+Nephew
    • 6.1.6 Aziyo Biologics
    • 6.1.7 Integra LifeSciences Corporation
    • 6.1.8 Coloplast
    • 6.1.9 Medtronic
    • 6.1.10 MTF Biologics
    • 6.1.11 Koninklijke DSM N.V.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS